Maloff Protect

Proguanil Hydrochloride, the active ingredient in Maloff Protect, is an antiprotozoal (antimalarial) presented as an oral tablet for oral use. It is combined with Atovaquone to prevent malaria infection and to treat acute uncomplicated malaria caused by Plasmodium falciparum in adults and children, under medical supervision.

GNH USA supplies Maloff Protect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable global logistics for both prophylactic and therapeutic needs.

Maloff Protect, containing the antimalarial combination of proguanil and atovaquone, is used in the malaria pathway for both prevention and treatment. - Malaria prophylaxis: prevents infection in travelers to endemic regions. - Uncomplicated Plasmodium falciparum malaria: treats acute infection. - Chemoprophylaxis for military personnel: provides protection during deployment.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: occasional cramping. - Vomiting: occasional expulsion of stomach contents. - Diarrhoea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Neutropenia: reduced white blood cell count. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Hemolysis: breakdown of red blood cells, especially in G6PD deficiency.

Precautions should be observed when using Maloff Protect. - Pregnancy: consult a healthcare provider before use. - Renal impairment: dose adjustment may be required. - Hepatic disease: monitor liver function during therapy. - Concomitant CYP450 inducers: may reduce drug efficacy. - Known hypersensitivity: avoid if allergic to any component. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Drug interactions may affect the safety or effectiveness of Maloff Protect. Major Interactions (Avoid): - Strong CYP2C8 inducers (e.g., rifampicin): may lower atovaquone levels. - Antacids containing aluminium or magnesium: decrease absorption of atovaquone. - QT‑prolonging agents: increase risk of cardiac arrhythmia. Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - HIV protease inhibitors: may raise atovaquone concentrations. - Sulfonamides: overlapping toxicity, monitor for adverse reactions.